Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses and Food Effect of NS-136 in Healthy Subjects

Next Previous
Search
Trial Profile

A Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses and Food Effect of NS-136 in Healthy Subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NS-136 (Primary)
  • Indications Alzheimer's disease; Schizophrenia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors NeuShen Therapeutics

    • Most Recent Events

    • 19 Nov 2024 Planned number of patients changed from 60 to 76.
    • 08 May 2024 According to a NeuShen Therapeutics media release, Successful results from this trial will pave the way for further clinical studies in patients with schizophrenia and other conditions associated with psychosis.
    • 08 May 2024 Status changed from not yet recruiting to recruiting, according to a NeuShen Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top